Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852070 | 0.87 | SIGMAR1 (0.62) | SIGMAR1HRH3CARM1PRMT6 | |
| SCHEMBL18672550 | 0.83 | SIGMAR1 (1.00) | SIGMAR1HTR1ASLC6A4HRH3 | |
| Hydrochloric Acid SCHEMBL27726278 | 0.82 | SIGMAR1 (0.97) | SIGMAR1HTR1ASLC6A4HRH3 | |
| SCHEMBL22813625 | 0.82 | HRH3 (0.83) | SIGMAR1HTR1ASLC6A4HRH3DRD2 | |
| SCHEMBL7319920 | 0.81 | SIGMAR1 (0.69) | SIGMAR1HTR1ASLC6A4OPRM1DRD2 | |
| SCHEMBL19852049 | 0.80 | HRH3 (0.65) | SIGMAR1HTR1ASLC6A4HRH3DRD2 | |
| SCHEMBL15962434 | 0.80 | SIGMAR1 (0.82) | SIGMAR1DRD2HTR2B | |
| Hydrochloric Acid SCHEMBL7310794 | 0.80 | SIGMAR1 (0.67) | SIGMAR1HTR1ASLC6A4OPRM1DRD2 | |
| Hydrochloric Acid SCHEMBL10352286 | 0.79 | HRH3 (0.78) | SIGMAR1SLC6A4HRH3DRD2HTR2B | |
| SCHEMBL19852051 | 0.79 | CARM1 (0.64) | SIGMAR1HTR1ASLC6A4OPRM1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | SIGMAR1 612/4885HTR1A 13/4885SLC6A4 15/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | SIGMAR1 612/4885HTR1A 13/4885SLC6A4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.